BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that Seattle Genetics’ management will present a company overview at three upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website, www.seattlegenetics.com, under the “Investor and News” section.
|
Morgan Stanley Global Healthcare Unplugged Conference |
| Tuesday, September 14, 2010 |
| 3:20 p.m. Eastern Time (ET) |
| New York, NY |
|
Stifel Nicolaus Healthcare Conference 2010 |
| Thursday, September 16, 2010 |
| 2:40 p.m. ET |
| Boston, MA |
|
UBS Global Life Sciences Conference |
| Tuesday, September 21, 2010 |
| 2:30 p.m. ET |
| New York, NY |
About Seattle Genetics
Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company’s lead product candidate, brentuximab vedotin (SGN-35), is in a pivotal trial under a Special Protocol Assessment with the U.S. Food and Drug Administration. Brentuximab vedotin is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has five other clinical-stage programs: lintuzumab (SGN-33), dacetuzumab (SGN-40), SGN-70, SGN-75 and ASG-5ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, MedImmune, a subsidiary of AstraZeneca, Millennium: The Takeda Oncology Company and Progenics, as well as an ADC co-development agreement with Agensys, an affiliate of Astellas. More information can be found at www.seattlegenetics.com.
CONTACT:
Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
[email protected]
KEYWORDS: United States North America Massachusetts New York Washington
INDUSTRY KEYWORDS: Health Biotechnology Genetics Oncology Pharmaceutical
MEDIA:
| Logo |